SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,804,764 | +405.6% | 204,626 | +377.7% | 0.03% | +400.0% |
Q2 2023 | $4,905,808 | -39.8% | 42,838 | -27.6% | 0.01% | -40.0% |
Q1 2023 | $8,150,991 | +56.4% | 59,138 | +47.0% | 0.01% | +66.7% |
Q4 2022 | $5,211,967 | +15.2% | 40,222 | -2.5% | 0.01% | 0.0% |
Q3 2022 | $4,523,000 | +36.4% | 41,257 | -6.7% | 0.01% | +50.0% |
Q2 2022 | $3,316,000 | -0.2% | 44,235 | +4.0% | 0.00% | +33.3% |
Q1 2022 | $3,323,000 | +33.0% | 42,535 | +53.4% | 0.00% | +50.0% |
Q4 2021 | $2,498,000 | -2.6% | 27,735 | 0.0% | 0.00% | -33.3% |
Q3 2021 | $2,565,000 | +36.4% | 27,735 | 0.0% | 0.00% | +50.0% |
Q2 2021 | $1,880,000 | -39.7% | 27,735 | -33.7% | 0.00% | -33.3% |
Q1 2021 | $3,117,000 | -58.8% | 41,821 | -5.7% | 0.00% | -66.7% |
Q4 2020 | $7,561,000 | +14.1% | 44,349 | -6.0% | 0.01% | 0.0% |
Q3 2020 | $6,629,000 | +0.1% | 47,204 | +14.3% | 0.01% | 0.0% |
Q2 2020 | $6,624,000 | +80.6% | 41,315 | +10.2% | 0.01% | +50.0% |
Q1 2020 | $3,668,000 | -64.0% | 37,493 | -52.5% | 0.01% | -60.0% |
Q4 2019 | $10,193,000 | +45.2% | 78,993 | -15.2% | 0.02% | +36.4% |
Q3 2019 | $7,019,000 | -49.9% | 93,189 | +1.1% | 0.01% | -47.6% |
Q2 2019 | $14,007,000 | +41.8% | 92,181 | +11.2% | 0.02% | +40.0% |
Q1 2019 | $9,879,000 | -4.2% | 82,881 | -12.3% | 0.02% | -16.7% |
Q4 2018 | $10,309,000 | -27.2% | 94,463 | +7.8% | 0.02% | -14.3% |
Q3 2018 | $14,158,000 | +13.3% | 87,663 | -7.2% | 0.02% | +10.5% |
Q2 2018 | $12,491,000 | +137.8% | 94,500 | +33.3% | 0.02% | +137.5% |
Q1 2018 | $5,253,000 | +154.5% | 70,900 | +91.1% | 0.01% | +166.7% |
Q4 2017 | $2,064,000 | +134.5% | 37,100 | +91.2% | 0.00% | +200.0% |
Q3 2017 | $880,000 | +175.0% | 19,400 | +104.2% | 0.00% | 0.0% |
Q2 2017 | $320,000 | -24.3% | 9,500 | -33.6% | 0.00% | 0.0% |
Q1 2017 | $423,000 | +1.4% | 14,300 | -5.9% | 0.00% | 0.0% |
Q4 2016 | $417,000 | -67.3% | 15,200 | -26.9% | 0.00% | -50.0% |
Q3 2016 | $1,277,000 | +90.6% | 20,800 | +18.2% | 0.00% | +100.0% |
Q2 2013 | $670,000 | – | 17,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
IMS Capital Management | 32,215 | $774,000 | 0.91% |
Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |